Zacks Research Upgrades Marker Therapeutics (NASDAQ:MRKR) to “Strong-Buy”

Marker Therapeutics (NASDAQ:MRKR) was upgraded by investment analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Thursday, Zacks reports.

Other research analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating on shares of Marker Therapeutics in a research report on Friday, August 21st. Weiss Ratings downgraded Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Marker Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Marker Therapeutics Price Performance

NASDAQ:MRKR traded up $0.12 during trading hours on Thursday, reaching $1.04. 1,145,148 shares of the stock were exchanged, compared to its average volume of 86,015. Marker Therapeutics has a twelve month low of $0.84 and a twelve month high of $2.46. The firm has a 50 day moving average of $1.17 and a 200 day moving average of $1.33. The stock has a market cap of $17.34 million, a PE ratio of -2.54 and a beta of 1.53.

Marker Therapeutics (NASDAQ:MRKR) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.16. Equities research analysts anticipate that Marker Therapeutics will post -0.64 earnings per share for the current year.

Hedge Funds Weigh In On Marker Therapeutics

A hedge fund recently bought a new position in Marker Therapeutics stock. Concurrent Investment Advisors LLC purchased a new stake in Marker Therapeutics, Inc. (NASDAQ:MRKR) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 67,963 shares of the company’s stock, valued at approximately $100,000. Concurrent Investment Advisors LLC owned 0.41% of Marker Therapeutics at the end of the most recent reporting period. Institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. The company’s approach uses tumor-specific T cells designed to recognize multiple tumor-associated antigens, with the goal of addressing the heterogeneity of solid tumors and potentially reducing the likelihood of treatment resistance.

Marker’s lead program is MT-601, an autologous multi-antigen-specific T-cell therapy being evaluated for pancreatic ductal adenocarcinoma.